EGFR and sarcoma: The top oncogenic signatures that were significantly up- or downregulated in DSRCT compared to each of the other sarcomas were ranked by adjusted P-value and depicted in Fig. 1B. The finding of EGFR_UP.V1_UP and ERBB2_UP.V1_UP gene set enrichment in DSRCT compared to other sarcomas suggested a role for EGFR and ERBB2 pathway activation in these tumors.